We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
NUVAXOVID (SARS-CoV-2 rS [NVX-CoV2373]) COVID-19 VACCINE adjuvanted suspension for injection vial, Biocelect Pty Ltd , CON-962
Product name
NUVAXOVID (SARS-CoV-2 rS [NVX-CoV2373]) COVID-19 VACCINE adjuvanted suspension for injection vial
Sponsor name
Biocelect Pty Ltd
Consent start
Consent no.
CON-962
Duration
The consent is effective from 1 July 2022 until 19 January 2024
Standard
Therapeutic Goods Order No. 91 − Standard for labels of prescription and related medicines (TGO 91).
Non-compliance with standard
The product does not comply with the requirements of TGO 91 in the labels are international labels
Conditions imposed
The product must be supplied with the labels that were considered and agreed to as part of the evaluation under section 9D(3) of the Therapeutic Goods Act 1989, beingThe international carton referred to in the submission as followsUpdate of carton with the removal of two (2) agents for pH adjustment from the carton text as submitted 14 June 2022 Sodium hydroxide and hydrochloric acid. OR The labels that were considered and agreed to as part of the evaluation under section 25 of the Therapeutic Goods Act 1989, being the international vial and carton labels referred to in submission dated 19 January 2022
Import, Supply, &/or Export
Import and supply
Therapeutic product type
Prescription medicines